Axoltis Pharma, a French BioTech firm devoted to creating novel therapeutic options for neurodegenerative illnesses, at the moment publicizes the closing of a €18 million ($20.9 million) Collection A funding spherical as a way to develop its lead drug candidate, at present in section 2 medical trials in sufferers with ALS/Lou Gehrig’s illness.
FIDAT Ventures and Cenitz co-led this spherical with contributions from residents coalesced by way of an fairness crowdfunding marketing campaign on the Capital Cell platform, enterprise angels and the Le Cercle de Chiron syndicate.
Legacy traders, together with Norfoalk, the Fonds Régional Avenir Industrie Auvergne Rhône-Alpes (Auvergne Rhône-Alpes Regional Trade Future Fund), FaDièse 3, Simba Santé 2 (Angelor), in addition to the CEO of Axoltis, additionally participated within the spherical.
“At a time when BioTech funding stays notably difficult, the success of this spherical demonstrates that traders imagine in our technique,” mentioned Dr Yann Godfrin, CEO of Axoltis Pharma. “I want to lengthen my warmest because of the historic traders and newcomers for his or her belief, assist and enthusiasm, and the enlightening discussions we held over the course of their thorough due diligence throughout the previous few months.”
In 2025, a number of European BioTech startups working in neurodegenerative or adjoining neurological fields have secured new funding, providing context for Axoltis Pharma’s Collection A.
Belgium-based Augustine Therapeutics raised €77.7 million in March to advance HDAC6-inhibitor therapies for neuromuscular and neurodegenerative illnesses. The UK’s TRIMTECH Therapeutics secured €28.6 million to develop small-molecule degraders concentrating on protein-aggregate-driven situations corresponding to Alzheimer’s and Huntington’s. In the meantime, French startup EG 427 raised €27 million to progress its gene-regulation platform for continual neurological issues.
Collectively, these corporations attracted roughly €133 million in 2025, highlighting sustained investor curiosity throughout Europe in new approaches to neurology and neurodegeneration.
Axoltis’s elevate provides to this pattern and is notable throughout the French context, the place EG 427’s 2025 funding additionally underlines rising nationwide momentum in CNS-focused BioTech.
“This fundraising permits us to keep up our head begin within the medical improvement of a product that restores the blood-brain barrier. It additionally means we are able to proceed our discussions with world-class pharmaceutical corporations, with a view to a world partnership that may assist present sufferers with faster entry to this therapy,” provides Dr Godfrin.
Based in 2016, Axoltis Pharma develops medication for neurodegenerative and neurotraumatic illnesses with a excessive unmet medical want – corresponding to ALS.
ALS is without doubt one of the most typical neuromuscular illnesses on this planet, with roughly 400,000 circumstances. It primarily assaults motor neurons, the nerve cells that transmit alerts from the mind to the muscle tissue and allow motion.
The progressive destruction of those neurons results in rising muscle weak point, lack of mobility and speech, and in superior levels, paralysis and respiratory difficulties. Most sufferers die inside two to 5 years. 90% of circumstances are sporadic, with no recognized danger components, and there’s at present no remedy for ALS.
“Axoltis is creating a breakthrough therapy that would change the lives of thousands and thousands of sufferers. If it reaches its full potential, a whole bunch of traders would additionally reap important monetary advantages. This interprets right into a win-win scenario for society as an entire,” says Daniel Oliver Uriel, founder and CEO of Capital Cell.
It’s right here that the corporate seems to be to make progress as they develop NX210c, a cyclic peptide of 12 amino acids designed from essentially the most conserved and repeated sequence of SCO-spondin, a glycoprotein that performs a vital function within the improvement of the central nervous system throughout embryogenesis.
NX210c is a novel drug candidate for neurodegenerative or trauma-related issues, with blood-brain barrier restore, neuroprotective and neurotransmission enchancment properties.
“The passion, perseverance and resilience demonstrated by the Axoltis crew over the previous few months are distinctive within the present monetary local weather,” mentioned Dr Gilles Avenard, chairman of the Axoltis supervisory board.
The €18 million has been raised throughout two tranches, the second being contingent on outcomes from the ‘SEALS’ section 2 medical trial at present underway.
Launched on the finish of 2024, SEALS goals to guage the efficacy and tolerability of NX210c in 82 sufferers with ALS, throughout 16 investigation websites. The trial additionally measures how the drug candidate helps restore the blood-brain barrier, which turns into broken in lots of neurodegenerative issues corresponding to ALS, Alzheimer’s illness, a number of sclerosis and Parkinson’s illness. The final affected person was enrolled in mid-November. Outcomes are anticipated in Q2 2026.
The funds obtained will even assist the corporate pursue analysis into different neurological indications the place the properties of NX210c may ship a major affect, notably in repairing the blood-brain barrier.
“Axoltis Pharma combines a high-performance crew, a particular know-how and noteworthy improvement potential; we’re delighted to be working alongside the corporate to any extent further,” mentioned Frédéric Picq, co-founder and accomplice at Cenitz.
